Isabel C Arrillaga-Romany

12PUBLICATIONS
155CO-AUTHORS
Molecular targetsImmunogenetics (incl. genetic immunology)Ship and platform structures (incl. maritime hydrodynamics)Gene and molecular therapyNeural engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

|Feb 06, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes.

Tyler A Lanman, Gilbert Youssef, Raymond Huang

|Apr 08, 2024
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.

Isabel Arrillaga-Romany, Julie J Miller

|Mar 06, 2024
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Isabel Arrillaga-Romany, Andrew Lassman, Susan L McGovern

|Feb 22, 2024
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.

Yazmin Odia, Matthew D Hall, Timothy Francis Cloughesy

|Feb 09, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

Isabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia

Pageof 2

Frequent Collaborators

6 joint publications

Tracy T Batchelor

5 joint publications

Patrick Y Wen

3 joint publications

David A Reardon

3 joint publications

Minesh P Mehta